3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
10
Neoplasms, Plasma Cell
4
Pancreatic Neoplasms
3
Lymphoma, Non-Hodgkin
3
Leukemia
3
Breast Neoplasms
3
Ovarian Neoplasms
2
Myeloproliferative Disorders
2
Lymphoma
2
Glioblastoma
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Plasmacytoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia, Plasma Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Dexamethasone
21
Calcium Dobesilate
10
Melphalan
9
Bortezomib
8
Cyclophosphamide
7
Lenalidomide
6
pomalidomide
4
venetoclax
3
miridesap
3
daratumumab
3
ixazomib
2
belantamab mafodotin
2
Thalidomide
2
Doxycycline
2
Biopsy
2
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
2
selinexor
1
pegfilgrastim
1
isatuximab
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
carfilzomib
1
birtamimab
1
auricularum
1
Vinorelbine
1
Technetium Tc 99m Pyrophosphate
1
Technetium
1
Tacrolimus
1
Surveys and Questionnaires
1
Pharmaceutical Preparations
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Amyloidosis
×
Gemcitabine
×
Plasma cell
×
Clear all
NCT02791373
2018-04-03
ViGeM
Insel Gruppe AG, University Hospital Bern
Phase 2
Completed
136 enrolled